Shilpa Medicare Limited (SHILPAMED) - Net Assets
Based on the latest financial reports, Shilpa Medicare Limited (SHILPAMED) has net assets worth Rs24.39 Billion INR (≈ $263.72 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs34.95 Billion ≈ $377.98 Million USD) and total liabilities (Rs10.57 Billion ≈ $114.27 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SHILPAMED asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs24.39 Billion |
| % of Total Assets | 69.77% |
| Annual Growth Rate | 24.82% |
| 5-Year Change | 61.07% |
| 10-Year Change | 231.93% |
| Growth Volatility | 29.21 |
Shilpa Medicare Limited - Net Assets Trend (2006–2025)
This chart illustrates how Shilpa Medicare Limited's net assets have evolved over time, based on quarterly financial data. Also explore Shilpa Medicare Limited total assets for the complete picture of this company's asset base.
Annual Net Assets for Shilpa Medicare Limited (2006–2025)
The table below shows the annual net assets of Shilpa Medicare Limited from 2006 to 2025. For live valuation and market cap data, see Shilpa Medicare Limited market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs23.64 Billion ≈ $255.63 Million |
+31.32% |
| 2024-03-31 | Rs18.00 Billion ≈ $194.66 Million |
+1.44% |
| 2023-03-31 | Rs17.74 Billion ≈ $191.89 Million |
-2.03% |
| 2022-03-31 | Rs18.11 Billion ≈ $195.87 Million |
+23.42% |
| 2021-03-31 | Rs14.67 Billion ≈ $158.70 Million |
+11.05% |
| 2020-03-31 | Rs13.21 Billion ≈ $142.91 Million |
+11.05% |
| 2019-03-31 | Rs11.90 Billion ≈ $128.69 Million |
+10.20% |
| 2018-03-31 | Rs10.80 Billion ≈ $116.78 Million |
+18.16% |
| 2017-03-31 | Rs9.14 Billion ≈ $98.83 Million |
+28.33% |
| 2016-03-31 | Rs7.12 Billion ≈ $77.01 Million |
+26.86% |
| 2015-03-31 | Rs5.61 Billion ≈ $60.71 Million |
+38.10% |
| 2014-03-31 | Rs4.06 Billion ≈ $43.96 Million |
+23.49% |
| 2013-03-31 | Rs3.29 Billion ≈ $35.60 Million |
+17.20% |
| 2012-03-31 | Rs2.81 Billion ≈ $30.37 Million |
+19.75% |
| 2011-03-31 | Rs2.35 Billion ≈ $25.36 Million |
+131.57% |
| 2010-03-31 | Rs1.01 Billion ≈ $10.95 Million |
+71.88% |
| 2009-03-31 | Rs589.21 Million ≈ $6.37 Million |
+5.21% |
| 2008-03-31 | Rs560.02 Million ≈ $6.06 Million |
+33.95% |
| 2007-03-31 | Rs418.09 Million ≈ $4.52 Million |
+19.40% |
| 2006-03-31 | Rs350.17 Million ≈ $3.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shilpa Medicare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1097088500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs10.97 Billion | 46.25% |
| Common Stock | Rs97.76 Million | 0.41% |
| Other Comprehensive Income | Rs523.26 Million | 2.21% |
| Other Components | Rs12.13 Billion | 51.14% |
| Total Equity | Rs23.72 Billion | 100.00% |
Shilpa Medicare Limited Competitors by Market Cap
The table below lists competitors of Shilpa Medicare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Quidel Corporation
NASDAQ:QDEL
|
$860.55 Million |
|
Gryphon Capital Income Trust
AU:GCI
|
$860.70 Million |
|
Imperial Metals Corporation
TO:III
|
$860.96 Million |
|
Shenyu Communication Technology Inc
SHE:300563
|
$861.40 Million |
|
Bergman & Beving AB (publ)
ST:BERG-B
|
$860.09 Million |
|
GL Events SA
PA:GLO
|
$859.42 Million |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
$859.33 Million |
|
Shanghai Shuixing Home Textile Co Ltd Class A
SHG:603365
|
$859.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shilpa Medicare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,086,941,000 to 23,722,364,000, a change of 5,635,423,000 (31.2%).
- Net income of 782,930,000 contributed positively to equity growth.
- Share repurchases of 4,891,034,000 reduced equity.
- New share issuances of 4,891,034,000 increased equity.
- Other comprehensive income increased equity by 111,465,000.
- Other factors increased equity by 4,741,028,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs782.93 Million | +3.3% |
| Share Repurchases | Rs4.89 Billion | -20.62% |
| Share Issuances | Rs4.89 Billion | +20.62% |
| Other Comprehensive Income | Rs111.47 Million | +0.47% |
| Other Changes | Rs4.74 Billion | +19.99% |
| Total Change | Rs- | 31.16% |
Book Value vs Market Value Analysis
This analysis compares Shilpa Medicare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 101.84x to 3.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs3.99 | Rs406.65 | x |
| 2007-03-31 | Rs4.01 | Rs406.65 | x |
| 2008-03-31 | Rs4.39 | Rs406.65 | x |
| 2009-03-31 | Rs4.48 | Rs406.65 | x |
| 2010-03-31 | Rs7.66 | Rs406.65 | x |
| 2011-03-31 | Rs16.06 | Rs406.65 | x |
| 2012-03-31 | Rs19.18 | Rs406.65 | x |
| 2013-03-31 | Rs21.78 | Rs406.65 | x |
| 2014-03-31 | Rs25.71 | Rs406.65 | x |
| 2015-03-31 | Rs35.31 | Rs406.65 | x |
| 2016-03-31 | Rs45.56 | Rs406.65 | x |
| 2017-03-31 | Rs117.62 | Rs406.65 | x |
| 2018-03-31 | Rs67.37 | Rs406.65 | x |
| 2019-03-31 | Rs73.45 | Rs406.65 | x |
| 2020-03-31 | Rs81.53 | Rs406.65 | x |
| 2021-03-31 | Rs181.37 | Rs406.65 | x |
| 2022-03-31 | Rs109.07 | Rs406.65 | x |
| 2023-03-31 | Rs102.72 | Rs406.65 | x |
| 2024-03-31 | Rs104.19 | Rs406.65 | x |
| 2025-03-31 | Rs121.80 | Rs406.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shilpa Medicare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.09%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.40x
- Recent ROE (3.30%) is below the historical average (12.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 11.32% | 8.32% | 1.05x | 1.30x | Rs4.63 Million |
| 2007 | 16.97% | 10.51% | 1.05x | 1.54x | Rs29.14 Million |
| 2008 | 20.21% | 11.81% | 0.53x | 3.22x | Rs57.20 Million |
| 2009 | -1.78% | -0.63% | 0.75x | 3.76x | Rs-69.09 Million |
| 2010 | 42.06% | 16.08% | 1.02x | 2.58x | Rs324.68 Million |
| 2011 | 21.96% | 17.00% | 0.84x | 1.54x | Rs268.81 Million |
| 2012 | 14.91% | 12.96% | 0.73x | 1.57x | Rs135.81 Million |
| 2013 | 14.77% | 12.75% | 0.67x | 1.72x | Rs153.00 Million |
| 2014 | 19.09% | 13.80% | 0.81x | 1.71x | Rs360.25 Million |
| 2015 | 13.59% | 12.01% | 0.68x | 1.67x | Rs194.72 Million |
| 2016 | 15.26% | 16.99% | 0.62x | 1.45x | Rs373.65 Million |
| 2017 | 11.74% | 14.74% | 0.53x | 1.50x | Rs159.55 Million |
| 2018 | 9.70% | 14.05% | 0.50x | 1.38x | Rs-32.62 Million |
| 2019 | 9.37% | 16.00% | 0.44x | 1.34x | Rs-74.98 Million |
| 2020 | 11.75% | 17.37% | 0.45x | 1.50x | Rs232.17 Million |
| 2021 | 9.99% | 16.42% | 0.34x | 1.78x | Rs-862.60K |
| 2022 | 3.33% | 5.32% | 0.40x | 1.58x | Rs-1.22 Billion |
| 2023 | -1.82% | -3.12% | 0.36x | 1.63x | Rs-2.11 Billion |
| 2024 | 1.76% | 2.76% | 0.37x | 1.71x | Rs-1.49 Billion |
| 2025 | 3.30% | 6.09% | 0.39x | 1.40x | Rs-1.59 Billion |
Industry Comparison
This section compares Shilpa Medicare Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shilpa Medicare Limited (SHILPAMED) | Rs24.39 Billion | 11.32% | 0.43x | $860.12 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, … Read more